---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-26-000015"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:37:04.041763+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q4 revenue up 29% to $77.1M, EPS $1.53; guides 2026 LUPKYNIS sales $305M-$315M

## Summary
- LUPKYNIS net product sales for FY 2025: $271.3M, up 25% YoY; Q4 $74.2M, up 29%.
- Net income for FY 2025: $287.2M ($2.07 diluted EPS) vs $5.8M ($0.04) in 2024; includes $173.0M tax benefit.
- Cash, equivalents, restricted cash & investments: $398.0M at Dec 31, 2025; generated $135.7M from operations.
- 2026 guidance: total revenue $315M-$325M; LUPKYNIS net sales $305M-$315M (12-16% growth).
- Initiated clinical study of aritinercept (BAFF/APRIL inhibitor); plan another autoimmune study in H1 2026.

## SEC filing metadata
- accession: 0001600620-26-000015
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/0001600620-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/auph-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-26-000015
- JSON: https://secwatch.observer/filing/0001600620-26-000015.json
- Plain text: https://secwatch.observer/filing/0001600620-26-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.